0001209191-18-064381.txt : 20181231
0001209191-18-064381.hdr.sgml : 20181231
20181231144232
ACCESSION NUMBER: 0001209191-18-064381
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180930
FILED AS OF DATE: 20181231
DATE AS OF CHANGE: 20181231
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BioLexis Pte Ltd.
CENTRAL INDEX KEY: 0001716335
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 181259524
BUSINESS ADDRESS:
STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE
CITY: SINGAPORE
STATE: U0
ZIP: 068877
BUSINESS PHONE: 962 6 582 7999
MAIL ADDRESS:
STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE
CITY: SINGAPORE
STATE: U0
ZIP: 068877
FORMER NAME:
FORMER CONFORMED NAME: GMS Tenshi Holdings Pte. Ltd
DATE OF NAME CHANGE: 20170906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pillai Arun Kumar
CENTRAL INDEX KEY: 0001717437
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 181259525
MAIL ADDRESS:
STREET 1: #30, "GALAXY," 1ST MAIN
STREET 2: J.P. NAGAR 3RD PHASE
CITY: BANGALORE
STATE: K7
ZIP: 560078
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sukhtian Faisal Ghiath
CENTRAL INDEX KEY: 0001716033
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 181259526
MAIL ADDRESS:
STREET 1: 7TH CIRCLE, ZAHRAN ST.
STREET 2: ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909
CITY: AMMAN
STATE: M2
ZIP: 11844
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2018-09-30
2018-10-02
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001716335
BioLexis Pte Ltd.
36 ROBINSON ROAD
#13-01 CITY HOUSE
SINGAPORE
U0
068877
SINGAPORE
1
0
1
0
0001717437
Pillai Arun Kumar
#30, 1ST MAIN
J.P. NAGAR 3RD PHASE
BANGALORE
K7
560078
INDIA
1
0
1
0
0001716033
Sukhtian Faisal Ghiath
7TH CIRCLE, ZAHRAN STREET
ZAHRAN PLAZA BLDG, 4TH FLOOR
AMMAN
M2
11844
JORDAN
1
0
1
0
Series A-1 Convertible Preferred Stock
2018-09-30
4
J
0
1468
0.00
A
Common Stock
221937
60203
D
Each share of the Series A-1 Convertible Preferred Stock (the "Series A-1") is convertible into shares of the Issuer's common stock, par value $0.01 per share ("Shares") at any time at the election of the holder. The Series A-1 has no expiration date.
Represents shares of Series A-1 received by BioLexis Pte Ltd. ("BioLexis") as a payment-in-kind dividend on previously acquired Series A-1.
These securities are held of record by BioLexis. Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.
By virtue of the relationships described above in Footnote 3, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
This Form 4/A to Form 4 filed with the Securities and Exchange Commission on 10/2/2018 is being filed to report the correct number of shares acquired and their corresponding underlying securities in Columns 5 and 7, respectively. The Reporting Person received 1,468 shares of Series A-1 Convertible Preferred Securities convertible into 221,937 shares of Common Stock on September 30, 2018 instead of the amount previously reported.
/s/ Faisal G. Sukhtian
2018-12-31
/s/ Arun Kumar Pillai
2018-12-31
/s/ Ghiath M. Sukhtian
2018-12-31